NasdaqGS - Delayed Quote • USD
Anavex Life Sciences Corp. (AVXL)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:38 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 2 | 2 | 2 | 2 |
Avg. Estimate | -0.11 | -0.12 | -0.48 | -0.64 |
Low Estimate | -0.13 | -0.15 | -0.57 | -0.87 |
High Estimate | -0.09 | -0.09 | -0.39 | -0.41 |
Year Ago EPS | -0.17 | -0.14 | -0.6 | -0.48 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 2 | 2 | 2 | 2 |
Avg. Estimate | -- | -- | -- | -- |
Low Estimate | -- | -- | -- | -- |
High Estimate | -- | -- | -- | -- |
Year Ago Sales | -- | -- | -- | -- |
Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.19 | -0.17 | -0.15 | -0.14 |
EPS Actual | -0.17 | -0.14 | -0.12 | -0.11 |
Difference | 0.02 | 0.03 | 0.03 | 0.03 |
Surprise % | 10.50% | 17.60% | 20.00% | 21.40% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.11 | -0.12 | -0.48 | -0.64 |
7 Days Ago | -0.11 | -0.12 | -0.48 | -0.64 |
30 Days Ago | -0.11 | -0.12 | -0.48 | -0.64 |
60 Days Ago | -0.11 | -0.12 | -0.48 | -0.64 |
90 Days Ago | -0.15 | -0.17 | -0.54 | -0.31 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | AVXL | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 35.30% | -- | -- | 6.50% |
Next Qtr. | 14.30% | -- | -- | 12.00% |
Current Year | 20.00% | -- | -- | 5.30% |
Next Year | -33.30% | -- | -- | 13.10% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | HC Wainwright & Co.: Buy to Buy | 1/3/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 11/28/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/8/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 7/20/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 6/29/2023 |
Reiterates | HC Wainwright & Co.: Buy | 5/2/2023 |
Related Tickers
ANVS Annovis Bio, Inc.
18.01
+32.43%
SAVA Cassava Sciences, Inc.
22.34
+2.81%
SAVAW Cassava Sciences, Inc.
0.4200
+35.48%
AXSM Axsome Therapeutics, Inc.
71.71
+0.27%
INMB INmune Bio, Inc.
11.29
+4.15%
ALT Altimmune, Inc.
7.26
+0.83%
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%
SLS SELLAS Life Sciences Group, Inc.
1.4600
-3.95%
NWBO Northwest Biotherapeutics, Inc.
0.4850
+1.68%
TGTX TG Therapeutics, Inc.
13.47
-3.16%